Description

Badges:

• First-in-Class Triple Agonist (GLP-1 + GIP + Glucagon)
• HPLC/MS Verified
• QR-linked COA per batch
• Secure Payments (Card + Crypto)
• Fast Canada Shipping

🔬 Science & Mechanism

Retatrutide activates three synergistic pathways:

• GLP-1 receptor agonism: slows digestion, boosts satiety, lowers appetite.
• GIP receptor agonism: enhances insulin secretion and glucose control.
• Glucagon receptor agonism: increases energy expenditure, mobilizing fat stores.

This “triple hit” creates greater metabolic balance and weight reduction than dual agonists.

📊 Clinical Evidence

• Phase 2 (NEJM, 2023):
  • 48 weeks, n=338 obese/overweight adults (no diabetes).
  • Mean loss: 24.2% body weight at 12 mg dose, vs 2.1% placebo.
  • Over 90% of participants achieved ≥5% loss.
• Nature Medicine 2024:
  • Liver fat content decreased by 82% at 48 weeks.
  • Improvements in ALT/AST and markers of fatty liver disease.
• Meta-analysis (2024, PMC):
  • Average across trials: ~14.3% weight loss, BMI reduction 5.4, waist reduction 10.5 cm, plus BP/glucose improvements.
• ADA 2024 (T2D cohort):
  • 12 mg retatrutide → 16.9% loss at 36 weeks in people with type 2 diabetes.

Reconstitution & Dosing Tables (Weight Loss Peptides)

Retatrutide (10 mg vial + 2 mL BAC water)

• Final concentration = 5 mg/mL → 50 mcg per unit (0.01 mL).

💉 Dosing Guide (Educational)

Weekly SubQ Titration (Phase 2 protocol):

• Escalation every 4 weeks as tolerated.
• Clinical trials used max dose of 12 mg weekly.

💧 Reconstitution (Example 10 mg vial)

• Add 2 mL bacteriostatic water.
• Final concentration: 1 mg = 0.2 mL (20 units).
• Example: 4 mg = 0.8 mL (80 units).

🧊 Storage

• Store lyophilized vials refrigerated (2–8 °C).
• Use within 30 days after reconstitution.
• Protect from light.

⚠️ Disclaimer

• For educational purposes only.
• Not yet FDA or Health Canada approved outside clinical trials.
• Customers assume responsibility for safe handling and research use.

❓ FAQ

Is this stronger than Tirzepatide?

Yes. Phase 2 trials suggest up to ~24% weight loss at 48 weeks, surpassing Tirzepatide’s ~21% at 72 weeks.

Is this available now?

Retatrutide is in advanced clinical trials and not yet widely commercialized. This is a research-grade peptide for educational exploration.

What about long-term safety?

Data is early; most common side effects are GI (similar to other GLP-1s). Ongoing studies are monitoring safety in obesity and diabetes cohorts.

📚 References

1. NEJM Phase 2 Trial (48 weeks, 24.2% loss at 12 mg)
   🔗 https://www.nejm.org/doi/full/10.1056/NEJMoa2301972
2. Nature Medicine — Liver fat & metabolic improvements
   🔗 https://www.nature.com/articles/s41591-024-03018-2
3. Wikipedia — Retatrutide overview
   🔗 https://en.wikipedia.org/wiki/Retatrutide
4. PMC Meta-Analysis — weight, BMI, waist, glucose, BP outcomes
   🔗 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12026077/
5. ADA Symposium (T2D data, 16.9% loss at 36 weeks)
   🔗 https://www.diabetes.org/newsroom/american-diabetes-association-highlights-novel-agent-retatrutide-results-substantial-weight-reduction-people-with-obesity-type-2-diabetes-during-late-breaking-symposium
6. Business Insider — pipeline “triple agonist” GLP-1 drugs
   🔗 https://www.businessinsider.com/upcoming-glp1-weight-loss-drugs-to-watch-2024-11
7. Wikipedia GLP-1/GIP/Glucagon poly-agonists
   🔗 https://en.wikipedia.org/wiki/GLP1_poly-agonist_peptides